Evidence map›Paper›PMID 32803561›Full record

ArticleDrug delivery and translational research2020

Liquid crystalline nanodispersion functionalized with cell-penetrating peptides improves skin penetration and anti-inflammatory effect of lipoic acid after in vivo skin exposure to UVB radiation.

Patrícia Mazureki Campos, Fabíola Garcia Praça, Samuel Vidal Mussi, Sônia Aparecida Figueiredo, Márcia Carvalho de Abreu Fantini, Maria José Vieira Fonseca, Vladimir P Torchilin, Maria Vitória Lopes Badra Bentley

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Patrícia Mazureki CamposSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Fabíola Garcia PraçaSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Samuel Vidal MussiCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 360 Huntington Avenue, Boston, MA, 02115, USA.
Sônia Aparecida FigueiredoSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Márcia Carvalho de Abreu FantiniPhysic Institute, University of São Paulo, 1371 Matão Street, São Paulo, SP, 05508-090, Brazil.
Maria José Vieira FonsecaSchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil.
Vladimir P TorchilinCenter for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 360 Huntington Avenue, Boston, MA, 02115, USA.
Maria Vitória Lopes Badra BentleySchool of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Avenida do Café, s/n, Ribeirão Preto, SP, 14040-903, Brazil. vbentley@usp.br.ORCID 0000-0002-1246-5433
Universidade de São Paulo · BRNortheastern University · USUniversidade de Ribeirão Preto · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico grant #465687/2014-8Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 99999.014600/2013-07Fundação de Amparo à Pesquisa do Estado de São Paulo grant #2018/08253-9
6 · The paper itself

Abstract

In this study, the development and the performance of a new targeted liquid crystalline nanodispersion (LCN) by the attachment of cell-penetrating peptides (CPP) onto their surfaces to improve skin delivery of lipoic acid (LA) were evaluated. For that, the synthesis and characterization of this new platform as well as its spatiotemporal analysis from in vitro and in vivo topical application were explored and extensively discussed in this paper. The TAT or D4 peptides were chosen as CPP due to specific target strategies by the charge grouping on the skin surface or target the overexpressed epidermal growth factor receptor (EGFR) of cell membrane of keratinocytes, respectively. Thus, the nanoparticle characterization results when taken together suggested that designed LCNs maintained their hexagonal phase structure, nanoscale particle size, and low polydispersity index even after drug, lipopolymers, and peptide additions, which are proved to be favorable for topical skin delivery. There were no statistical differences among the LCNs investigated, except for superficial charge of LCN conjugated with TAT which may have altered the LCN zeta potential due to cationic charge of TAT amino acid sequence compared with D4. The cumulative amounts of LA retained into the skin were determined to be even higher coming from the targeted LCNs. Moreover, the exogenous antioxidant application of the LA from the LCNs can prevent ROS damage, which was demonstrated by this study with the less myeloperoxidase (MPO) activity and decrease in cytokine levels (TNF-alpha and IL-1β) generated by the oxidative stress modulation. Together, the data presented highlights the potential of these targeted LCNs, and overall, opens new frontiers for preclinical trials.

Indexed as

Anti-Inflammatory AgentsCell-Penetrating PeptidesNanoparticlesThioctic AcidAnimalsMaleMiceSkinSkin AbsorptionUltraviolet RaysAnti-Inflammatory AgentsCell-Penetrating PeptidesThioctic AcidAnti-inflammatoryCell-penetrating peptideFunctionalizationLipoic acidLiquid crystalline phaseTopical delivery

Identifiers

PMID32803561
OpenAlexW3049182096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.